[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-aging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-aging":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,56,104,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100609063","the-effect-of-near-infrared-light-therapy-on-brain-function-and-cognition-in-young-and-older-adults-100609063",false,"NCT07209683","The Effect of Near-infrared Light Therapy on Brain Function and Cognition in Young and Older Adults","Age-specific Neurovascular Effects of Transcranial Photobiomodulation","Inclusion Criteria:\n\n* Age: 21-85 years of age\n* Adequate hearing and visual acuity to participate in the examinations\n* Ability to read and write in English\n* Competence to provide informed consent\n\nExclusion Criteria:\n\n* Active CNS disease including multiple sclerosis, uncontrolled seizures, active brain cancer\n* Cerebrovascular accident other than TIA within 60 days prior to Visit 0\n* Major psychiatric disease, including major depression not currently controlled on medications, alcohol or drug abuse\n* Participant currently uses commercial brain stimulation \u002F neuromodulation device or an experimental device as part of a research study, e.g. tDCS, tACS, TBS, DBS, TMS, TPBM, etc.\n* Participant currently takes dietary supplements with an expected cerebrovascular benefit, such as NAD- or NR-supplement, L-citrulline, urolithin\n* Unstable medical condition, including uncontrolled diabetes, chronic heart issues, heart failure, chronic obstructive pulmonary disease, Stage 2 hypertension uncontrolled by medication (\\>160\u002F100 mmHg)\n* Any other medical condition or medication which, in the opinion of investigator, would render the patient inappropriate or too unstable to complete the study protocol.\n* Pregnancy or trying to become pregnant in the next 1 months (self-reported), breastfeeding",true,"ALL","21 Years","85 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this pilot clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and cognitive function in older adults.\n\nThe main questions it aims to answer are:\n\n* Does tPBM enhance neurovascular coupling responses during memory and finger tapping tasks?\n* Are these improvements linked to better cognitive performance and lower levels of brain inflammation and oxidative stress?\n\nResearchers will compare an active tPBM treatment arm to a sham treatment arm to see if tPBM leads to measurable improvements in brain activity and cognitive function compared to no active stimulation.\n\nParticipants will:\n\n* Receive either active tPBM or sham stimulation sessions for 4 weeks, every other day using a portable intervention device.\n* Complete questionnaires and an iPAD-based cognitive testing protocol\n* Complete memory and motor tasks while their brain activity is measured using non-invasive techniques: simultaneous functional near-infrared spectroscopy (fNIRS) and electroencephalography (EEG), transcranial doppler (TCD) flowmetry.\n* Retinal vessel reactivity will be measured during flickering light stimulus using a special camera (dynamic vessel analysis, DVA).\n* Provide blood samples to test for biomarkers of inflammation, oxidative stress and brain cell damage.",[28,29,30,31,32],"Cognition","Neurovascular Coupling Mechanism and Cognitive Function","Neurovascular Control","Brain Aging","Brain Activity",[34,35,36,37,38,39,40,41,42],"transcranial photobiomodulation","neurovascular coupling","aging","cognitive function","near-infrared spectroscopy","electroencephalography","dynamic vessel analysis","home-based intervention","randomized double-blinded clinical trial","RECRUITING","2026-02-04",{"date":46,"type":47},"2026-02-06","ACTUAL",{"date":49,"type":47},"2025-10-01",{"date":51,"type":22},"2026-12-31",{"name":53,"class":54},"University of Oklahoma","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":16,"sex":17,"minAge":63,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":23,"phases":66,"briefSummary":68,"conditions":69,"keywords":75,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":55},"100623137","phase-2-ala-enriched-nutrition-for-prevention-of-cognitive-decline-in-apoe4-older-adults-100623137","NCT07392723","ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults","Alpha Linolenic Acid-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults With Mild Cognitive Impairment: Targeting Cerebrovascular and Blood-brain Barrier Health","Inclusion Criteria:\n\n* Age 60 years or older\n* Have amnestic Mild Cognitive Impairment (MCI) - memory problems that do not interfere with daily life.\n* Carry at least one APOE4 gene allele (determined by a blood test).\n* Be fluent in English or Spanish.\n* Have a study partner (family member or friend) who can provide information about daily function.\n* Have the ability to give informed consent and comply with study visits and procedures.\n\nExclusion Criteria:\n\n* A diagnosis of dementia or any other brain disease that significantly affects thinking or memory (e.g., Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy, traumatic brain injury).\n* History of stroke or other major neurological condition.\n* Short life expectancy due to end-stage disease or other serious medical condition.\n* Active cancer treatment that could interfere with study participation.\n* Allergy or sensitivity to flaxseed oil or corn oil.\n* Current use of flaxseed, flax oil, or fish oil supplements more than once per week.\n* MRI contraindications, such as pacemakers, metallic implants, or severe claustrophobia.\n* Current or past history of prostate cancer, regardless of remission status, OR a prostate-specific antigen (PSA) level \\> 20 ng\u002FmL at screening.\n* Use of experimental Alzheimer's treatments (e.g., amyloid monoclonal antibodies) unless on a stable regimen as confirmed by the treating physician.","60 Years",{"count":65,"type":22},20,[67],"PHASE2","This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults with mild cognitive impairment and APOE4 genotype. By targeting the endogenous synthesis of docosahexaenoic acid (DHA) through ALA supplementation, the investigators aim to overcome the limitations of direct DHA supplementation, particularly in APOE4 carriers who exhibit low brain DHA levels and impaired blood-brain barrier function. This innovative approach offers a safe, cost-effective, and easily implementable therapeutic strategy for older adults at high risk for Alzheimer's dementia, especially APOE4 carriers, addressing a critical need given the limited cognitive benefits and significant adverse events of current amyloid-clearing drugs in this population.",[70,71,72,73,31,74],"Cognitive Dysfunction","Alzheimer Disease","Blood-Brain Barrier","Apolipoprotein E, Deficiency or Defect of","Fatty Acids, Omega-3",[76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,95],"Alpha-Linolenic Acid","Flaxseed Oil","Apolipoprotein E4","Nutritional Intervention","APOE4 Dysfunction","Cognitive Function","Brain MRI","Blood Biomarkers","Vascular Integrity","Neurodegeneration","Aging Brain","Memory Loss Prevention","AD Prevention Trial","Alzheimer's Disease","Cognitive decline prevention","Blood-brain barrier","Dementia prevention","Older adults","Biomarkers","Magnetic resonance imaging (MRI)","2026-01-30",{"date":46,"type":47},{"date":99,"type":47},"2025-01-12",{"date":101,"type":22},"2027-10",{"name":103,"class":54},"Michal Schnaider Beeri, Ph.D.",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":16,"sex":17,"minAge":111,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":4},"100622116","haematococcus-pluvialis-astaxanthin-for-brain-aging-100622116","NCT07379437","Haematococcus Pluvialis Astaxanthin for Brain Aging","Effects and Mechanism of Haematococcus Pluvialis Astaxanthin on Inhibiting Brain Aging Through Improving Mitochondrial Function","Inclusion Criteria:\n\nCognitive functionally normal elderly individuals aged 50 years or older with baseline MoCA scores near the borderline for mild cognitive impairment (MCI); subjects reporting age-related forgetfulness; community-dwelling residents who can cooperate with the research team to complete the intervention study.\n\nExclusion Criteria:\n\nIndividuals with hearing or language expression impairments that hinder communication; those with severe cardiovascular, cerebrovascular, hepatic, renal, or other organ diseases, or malignant tumors; individuals who have been taking astaxanthin or other antioxidant dietary supplements within the past month; those who have recently used medications that may affect neurological function; and individuals who are unable to undergo cognitive function assessment or refuse to sign an informed consent form.","50 Years",{"count":113,"type":22},120,[25],"We recruit community-dwelling older adults aged 50 and above for a 6-month intervention. Participants are divided into three groups:\n\nPlacebo Group, Low-Dose Group ( 6 mg\u002Fd Haematococcus pluvialis Astaxanthin), High-Dose Group (12 mg\u002Fd Haematococcus pluvialis Astaxanthin).\n\nPeripheral blood samples and Other tests are collected at baseline, 3 months, and 6 months to measure mitochondrial function and oxidative stress levels.\n\nAssessments include: 1.Cognitive \\& Neurophysiological Assessment: Using the MoCA (Montreal Cognitive Assessmentscale) and ERP (specifically P300) monitoring. 2.Brain Imaging: MRI (Magnetic resonance imaging) is used to analyze changes in brain function. 3.Metabolomics: A series of laboratory techniques are used to analyze routine metabolic indices, plasma astaxanthin, mitochondrial function, oxidative stress markers, and cognition-related neurobiomarkers.",[31],"NOT_YET_RECRUITING","2026-01-27",{"date":96,"type":47},{"date":121,"type":22},"2026-05-01",{"date":123,"type":22},"2027-02-01",{"name":125,"class":54},"Capital Medical University",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":16,"sex":17,"minAge":134,"maxAge":19,"enrollmentInfo":135,"targetDuration":4,"studyType":23,"phases":137,"briefSummary":138,"conditions":139,"keywords":140,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":55},"100526637","avocog---the-effect-of-daily-avocado-intake-on-cognitive-function-in-older-adults-100526637","NCT06137339","AvoCog - the Effect of Daily Avocado Intake on Cognitive Function in Older Adults","AvoCog - The Effect of Daily Avocado Intake on Cognitive Function in Older Adults","AvoCog","Inclusion Criteria:\n\n* Males and females aged 65-85 years\n* Good general health with no concomitant disease\n* BMI 18.5 - 35 kg\u002Fm2\n* Mini Mental State Exam ≥26\n* Reports consuming ≤2 medium avocados per month\n* Reports consuming ≤3 servings of carotenoid-rich foods per week and ≤3 servings of fruits and vegetables per day\n* Skin carotenoid content \\\u003C400\n\nExclusion Criteria:\n\n* Unwilling or unable to consume avocado\n* Latex allergy\n* Consistently taking lutein + zeaxanthin supplements\n* Skin carotenoid content ≥400\n* Central neurological disease such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, brain tumor, etc.\n* Serious medical risk: cancer requiring chemotherapy or radiation within the past 5 years, recent cardiac event (i.e. heart attack, etc.)\n* Diabetes mellitus or uncontrolled hypertension\n* Use of psychoactive or investigational medications\n* Consumption of ≥3 alcoholic drinks per day or substance abuse\n* Unable to undergo MRI","65 Years",{"count":136,"type":22},70,[25],"The goal of this clinical trial is to determine if adding avocados to the diet of impacts cognition in 70 older adults, age 65-85, without dementia. We will test for change in functional MRI, cognitive performance, and brain blood flow. Intervention group participants will be asked to consume 1 avocado per day for 12 weeks. Participants in the control group will be asked to continue their normal intake for 12 weeks. Throughout the study, participants will be asked to perform cognitive tests, MRI, blood tests, and questionnaires.",[31],[141,142,143,144,28,145],"Older Adults","Brain Health","Avocado","Brain Imaging","Dietary Intervention","2024-08-20",{"date":148,"type":47},"2024-08-22",{"date":150,"type":47},"2024-04-09",{"date":152,"type":22},"2025-12",{"name":154,"class":54},"University of Kansas Medical Center"]